Proteasome inhibition promotes regression of left ventricular hypertrophy - PubMed (original) (raw)

. 2008 Feb;294(2):H645-50.

doi: 10.1152/ajpheart.00196.2007. Epub 2007 Nov 21.

Affiliations

• PMID: 18032525
• DOI: 10.1152/ajpheart.00196.2007

Free article

Proteasome inhibition promotes regression of left ventricular hypertrophy

William E Stansfield et al. Am J Physiol Heart Circ Physiol. 2008 Feb.

Free article

Abstract

Current research in left ventricular hypertrophy (LVH) has largely focused on its progression and therapeutic mechanisms to prevent or slow its development. Few studies have centered on the regression or treatment of existing LVH. Nuclear factor-kappaB (NF-kappaB) is an inflammatory transcription factor that has been shown to be involved in LVH development. We hypothesized that proteasome-mediated NF-kappaB inhibition would prevent the development of LVH and promote its regression. A murine model of reversible hypertrophy was employed by administering isoproterenol (Iso) subcutaneously for 7-14 days. The proteasome inhibitor, PS-519, was delivered both concurrently and after Iso treatment. LVH was quantified by heart weight-to-body weight ratios, histology, transthoracic echocardiography, and hypertrophic gene expression. After 7 days of Iso treatment, all measures indicated successful development of LVH. Another group was treated for 7 days and then observed for an additional 7 days. This group experienced normalization of Iso-induced cell size, wall thickness, and beta-myosin heavy chain expression. When administered concurrently, PS-519 prevented Iso-induced LVH at 7 days. Furthermore, when PS-519 was given to animals during the second week of continued Iso treatment, these animals also experienced regression of hypertrophy by several measures. The success of proteasome inhibition in preventing LVH development and in promoting LVH regression, even in the face of continued hypertrophic stimulation, demonstrates its potential use as a clinically accessible strategy for treating patients with a variety of LVH-associated cardiomyopathies.

PubMed Disclaimer

Similar articles

• Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophy.
  Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH. Andersen NM, et al. J Surg Res. 2012 Nov;178(1):105-9. doi: 10.1016/j.jss.2012.03.003. Epub 2012 Mar 22. J Surg Res. 2012. PMID: 22464396 Free PMC article.
• Vitamin D attenuates pro-inflammatory TNF-α cytokine expression by inhibiting NF-кB/p65 signaling in hypertrophied rat hearts.
  Al-Rasheed NM, Al-Rasheed NM, Bassiouni YA, Hasan IH, Al-Amin MA, Al-Ajmi HN, Mohamad RA. Al-Rasheed NM, et al. J Physiol Biochem. 2015 Jun;71(2):289-99. doi: 10.1007/s13105-015-0412-1. Epub 2015 May 1. J Physiol Biochem. 2015. PMID: 25929726
• Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction.
  Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, Meyer TE, Norton GR. Woodiwiss AJ, et al. Circulation. 2001 Jan 2;103(1):155-60. doi: 10.1161/01.cir.103.1.155. Circulation. 2001. PMID: 11136701
• Echocardiographic quantification of left ventricular mass: prognostic implications.
  Swamy RS, Lang RM. Swamy RS, et al. Curr Cardiol Rep. 2010 May;12(3):277-82. doi: 10.1007/s11886-010-0104-y. Curr Cardiol Rep. 2010. PMID: 20424973 Review.
• Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients.
  Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Verdecchia P, et al. Ital Heart J. 2004 Jul;5(7):505-10. Ital Heart J. 2004. PMID: 15487267 Review.

Cited by

• MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice.
  Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH, Wang DZ. Callis TE, et al. J Clin Invest. 2009 Sep;119(9):2772-86. doi: 10.1172/JCI36154. Epub 2009 Aug 10. J Clin Invest. 2009. PMID: 19726871 Free PMC article.
• Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.
  Drews O, Taegtmeyer H. Drews O, et al. Antioxid Redox Signal. 2014 Dec 10;21(17):2322-43. doi: 10.1089/ars.2013.5823. Epub 2014 Oct 1. Antioxid Redox Signal. 2014. PMID: 25133688 Free PMC article. Review.
• Aging and dietary restriction effects on ubiquitination, sumoylation, and the proteasome in the heart.
  Li F, Zhang L, Craddock J, Bruce-Keller AJ, Dasuri K, Nguyen A, Keller JN. Li F, et al. Mech Ageing Dev. 2008 Sep;129(9):515-21. doi: 10.1016/j.mad.2008.04.007. Epub 2008 Apr 30. Mech Ageing Dev. 2008. PMID: 18533226 Free PMC article.
• Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophy.
  Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH. Andersen NM, et al. J Surg Res. 2012 Nov;178(1):105-9. doi: 10.1016/j.jss.2012.03.003. Epub 2012 Mar 22. J Surg Res. 2012. PMID: 22464396 Free PMC article.
• Clarifying the cardiac proteasome paradox: protein quality control.
  Glembotski CC. Glembotski CC. Circ Res. 2012 Aug 17;111(5):509-12. doi: 10.1161/CIRCRESAHA.112.275917. Circ Res. 2012. PMID: 22904038 Free PMC article. No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database